Status:
COMPLETED
Assessment of Coagulation and Thrombocyte Function After Termination of Ticagrelor
Lead Sponsor:
Örebro University, Sweden
Conditions:
PCI
Coronary Stents
Eligibility:
All Genders
45-85 years
Brief Summary
When ticagrelor should be discontinued prior to elective surgery is unclear. The risks of bleeding when it is continued peri-operatively have to be weighed against the risk of coronary artery thrombos...
Detailed Description
Patients who have an acute coronary syndrome are today often treated by percutaneous coronary intervention (PCI) and insertion of one or several coronary stents. Subsequently, these patients are treat...
Eligibility Criteria
Inclusion
- \- Patients who are on the Cardiology Clinic's database at the University Hospital, Örebro and shall terminate ticagrelor after one year following PCI and stent placement would be identified and offered to take part in this study.
Exclusion
- \- Non-responders (not partial responders) to ticagrelor would be excluded from the study. Additionally, patients who are either taking NSAID's regularly or during the last 2 weeks prior to study start would also be excluded as those who have language or cognitive limitations.
Key Trial Info
Start Date :
September 1 2013
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
September 1 2015
Estimated Enrollment :
25 Patients enrolled
Trial Details
Trial ID
NCT02297971
Start Date
September 1 2013
End Date
September 1 2015
Last Update
September 29 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Hospital
Örebro, Sweden, 701 85